Natalizumab Switch to Moderate-Efficacy DMT Ups Disability Risk Natalizumab Switch to Moderate-Efficacy DMT Ups Disability Risk

Patients who switched to another high-efficacy therapy had improved disability and inflammatory outcomes.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news